<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:02:42Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10134336" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10134336</identifier>
        <datestamp>2023-04-28</datestamp>
        <setSpec>canmed</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cam45552" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
              <journal-id journal-id-type="publisher-id">CAM4</journal-id>
              <journal-title-group>
                <journal-title>Cancer Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-7634</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10134336</article-id>
              <article-id pub-id-type="pmcid">PMC10134336</article-id>
              <article-id pub-id-type="pmc-uid">10134336</article-id>
              <article-id pub-id-type="pmid">36540051</article-id>
              <article-id pub-id-type="pmid">36540051</article-id>
              <article-id pub-id-type="doi">10.1002/cam4.5552</article-id>
              <article-id pub-id-type="publisher-id">CAM45552</article-id>
              <article-id pub-id-type="other">CAM4-2022-08-3682.R1</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>RESEARCH ARTICLES</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Cancer Prevention</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the <styled-content style="fixed-case" toggle="no">PACCT</styled-content> study</article-title>
                <alt-title alt-title-type="left-running-head">Eggly et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cam45552-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Eggly</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8137-6098</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>egglys@karmanos.org</email>
                  </address>
                </contrib>
                <contrib id="cam45552-cr-0002" contrib-type="author">
                  <name>
                    <surname>Senft</surname>
                    <given-names>Nicole</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3617-7276</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0003" contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Seongho</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1120-073X</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0004" contrib-type="author">
                  <name>
                    <surname>Heath</surname>
                    <given-names>Elisabeth I.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1381-2713</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0005" contrib-type="author">
                  <name>
                    <surname>Jang</surname>
                    <given-names>Hyejeong</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4502-6215</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0006" contrib-type="author">
                  <name>
                    <surname>Moore</surname>
                    <given-names>Tanina F.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0232-348X</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0007" contrib-type="author">
                  <name>
                    <surname>Baidoun</surname>
                    <given-names>Fatmeh</given-names>
                  </name>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0008" contrib-type="author">
                  <name>
                    <surname>Manning</surname>
                    <given-names>Mark A.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5288-7238</contrib-id>
                  <xref rid="cam45552-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0009" contrib-type="author">
                  <name>
                    <surname>Penner</surname>
                    <given-names>Louis A.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0455-7696</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0010" contrib-type="author">
                  <name>
                    <surname>Albrecht</surname>
                    <given-names>Terrance L.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8907-6751</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0011" contrib-type="author">
                  <name>
                    <surname>Carducci</surname>
                    <given-names>Michael A.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7908-1215</contrib-id>
                  <xref rid="cam45552-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0012" contrib-type="author">
                  <name>
                    <surname>Lansey</surname>
                    <given-names>Dina</given-names>
                  </name>
                  <xref rid="cam45552-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45552-cr-0013" contrib-type="author">
                  <name>
                    <surname>Hamel</surname>
                    <given-names>Lauren M.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8910-7079</contrib-id>
                  <xref rid="cam45552-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="cam45552-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Oncology</named-content>
                <institution>Wayne State University/Karmanos Cancer Institute</institution>
                <city>Detroit</city>
                <named-content content-type="country-part">Michigan</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam45552-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychology</named-content>
                <institution>Oakland University</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">Michigan</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam45552-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</institution>
                <city>Baltimore</city>
                <named-content content-type="country-part">Maryland</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Susan Eggly, Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R., Detroit, MI 48201, USA.<break/>
Email: <email>egglys@karmanos.org</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="840">7</issue>
              <issue-id pub-id-type="doi">10.1002/cam4.v12.7</issue-id>
              <fpage>8604</fpage>
              <lpage>8613</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>04</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>24</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>08</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 Published by John Wiley & Sons Ltd.-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CAM4-12-8604.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="cam45552-sec-0001">
                  <title>Background</title>
                  <p>Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rates.</p>
                </sec>
                <sec id="cam45552-sec-0002">
                  <title>Methods</title>
                  <p>Physicians at two comprehensive cancer centers and Black and White men with prostate cancer participated. Patients were followed for 2 years to determine whether they became potentially eligible for an available therapeutic trial. Potentially eligible patients were randomized to receive a trials‐focused Question Prompt List or usual care. Patient–physician interactions were video‐recorded. Outcomes included communication quality and trial invitation rates. Descriptive analyses assessed associations between sociodemographic characteristics and eligibility and effects of the intervention on outcomes.</p>
                </sec>
                <sec id="cam45552-sec-0003">
                  <title>Results</title>
                  <p>Only 44 (22.1%) of participating patients (<italic toggle="no">n</italic> = 199) became potentially eligible for an available clinical trial. Patients with higher incomes were more often eligible (&gt;$80,000 vs. &lt;$40,000, adjusted OR = 6.06 [SD, 1.97]; $40,000–$79,000 vs. &lt;$40,000, adjusted OR = 4.40 [SD, 1.81]). Among eligible patients randomized to the intervention (<italic toggle="no">n</italic> = 19) or usual care (<italic toggle="no">n</italic> = 25), Black patients randomized to the intervention reported participating more actively than usual care patients, while White intervention patients reported participating less actively (difference, 0.41 vs. −0.34). Intervention patients received more trial invitations than usual care patients (73.7% vs. 60.0%); this effect was greater for Black (80.0% vs. 30.0%) than White patients (80.0% vs. 66.7%).</p>
                </sec>
                <sec id="cam45552-sec-0004">
                  <title>Conclusions</title>
                  <p>Findings suggest the greatest enrollment barrier is eligibility for an available trial, but a communication intervention can improve communication quality and trial invitation rates, especially for eligible Black patients.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical" id="cam45552-abs-0002">
                <p>This multisite study addressed two barriers to enrollment of Black and White men in prostate cancer clinical trials—patient eligibility and patient–physician communication. Findings showed eligibility, a systemic barrier, is the biggest barrier; but a simple Question Prompt List communication intervention can improve interpersonal barriers including communication quality and trial invitation rates, especially for Black patients.<boxed-text position="anchor" content-type="graphic" id="cam45552-blkfxd-0001"><graphic xlink:href="CAM4-12-8604-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="cam45552-kwd-0001">clinical trials</kwd>
                <kwd id="cam45552-kwd-0002">health disparities</kwd>
                <kwd id="cam45552-kwd-0003">patient–physician communication</kwd>
                <kwd id="cam45552-kwd-0004">prostate cancer</kwd>
                <kwd id="cam45552-kwd-0005">question prompt list</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01CA200718</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <page-count count="10"/>
                <word-count count="5548"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>April 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:27.04.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="CAM45552-cit-2001"><string-name><surname>Eggly</surname><given-names>S</given-names></string-name>, <string-name><surname>Senft</surname><given-names>N</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S</given-names></string-name>, et al. <article-title>Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the <styled-content style="fixed-case" toggle="no">PACCT</styled-content> study</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>:<fpage>8604</fpage>‐<lpage>8613</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.5552</pub-id>
</mixed-citation>
              </p>
            </notes>
          </front>
          <body id="cam45552-body-0001">
            <sec id="cam45552-sec-0005">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Cancer clinical trials test the safety and efficacy of promising treatments and translate new knowledge into tangible benefits for patients. However, only a small percentage of patients participate.<xref rid="cam45552-bib-0001" ref-type="bibr"><sup>1</sup></xref> Low accrual jeopardizes assessment of the safety and effectiveness of new approaches to cancer care, waste resources, and precludes follow‐up studies.</p>
              <p>Despite NIH and other professional society requirements to include people of color in clinical research,<xref rid="cam45552-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cam45552-bib-0003" ref-type="bibr"><sup>3</sup></xref> under‐enrollment is an even greater problem in these groups, especially among Black people.<xref rid="cam45552-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam45552-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="cam45552-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cam45552-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cam45552-bib-0008" ref-type="bibr"><sup>8</sup></xref> Inequitable enrollment limits the generalizability of findings<xref rid="cam45552-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cam45552-bib-0009" ref-type="bibr"><sup>9</sup></xref> and may represent inequitable access to high‐quality clinical care.<xref rid="cam45552-bib-0010" ref-type="bibr"><sup>10</sup></xref>
</p>
              <p>This problem is especially clear in prostate cancer, which is estimated to account for 27% of all cancer diagnoses and 11% of deaths in men in 2022.<xref rid="cam45552-bib-0011" ref-type="bibr"><sup>11</sup></xref> Black men are 1.73 times more likely to be diagnosed and 2.13 times more likely to die from prostate cancer than non‐Hispanic White men.<xref rid="cam45552-bib-0012" ref-type="bibr"><sup>12</sup></xref> Yet, accrual to prostate cancer clinical trials among Black men is disproportionately low,<xref rid="cam45552-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cam45552-bib-0014" ref-type="bibr"><sup>14</sup></xref> including among men with metastatic disease.<xref rid="cam45552-bib-0015" ref-type="bibr"><sup>15</sup></xref>
</p>
              <p>While enrollment barriers are complex and multilevel,<xref rid="cam45552-bib-0016" ref-type="bibr"><sup>16</sup></xref> research demonstrates that most patients are willing to participate, with little difference by race,<xref rid="cam45552-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam45552-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cam45552-bib-0019" ref-type="bibr"><sup>19</sup></xref> suggesting causes beyond individual preference. In this research, we examine two additional enrollment barriers that may disproportionately affect Black patients, one systemic and one interpersonal: eligibility for an available trial and patient–physician communication. We report on the first phase of a prospective, multi‐site, multilevel study, Partnering Around Cancer Clinical Trials (PACCT). Designed to better understand and improve participation in prostate cancer clinical trials, especially among Black men, PACCT included a prospective observational study examining eligibility, and, for a subset of participants, a prospective communication intervention study.</p>
              <p>The objective of the prospective observational study was to describe the proportion and socio‐demographic characteristics of patient participants who preliminarily met eligibility criteria for an available prostate cancer therapeutic clinical trial during the study period. We expected that sociodemographic characteristics, such as self‐identified race, age, income, and education, as well as self‐reported health status would be associated with likelihood of potential eligibility.<xref rid="cam45552-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam45552-bib-0020" ref-type="bibr"><sup>20</sup></xref>
</p>
              <p>The prospective interventional study focused on patient–physician clinical communication among the subset of patients identified as potentially eligible for an available trial. The objective was to examine whether a patient‐level communication intervention improved communication quality and rates of invitations to participate in an available prostate cancer therapeutic clinical trial. We expected that patients who received the intervention, compared to patients in the usual care group, would experience better communication quality and be more likely to receive an invitation. We further expected that intervention effects would be greater for Black than for White participants, given documented disparities in communication quality during interactions with Black and with White patients.<xref rid="cam45552-bib-0021" ref-type="bibr"><sup>21</sup></xref>
</p>
            </sec>
            <sec sec-type="methods" id="cam45552-sec-0006">
              <label>2</label>
              <title>METHODS</title>
              <sec id="cam45552-sec-0007">
                <label>2.1</label>
                <title>Study design</title>
                <p>Study design included a prospective descriptive study and a prospective randomized clinical trial. In the original protocol,<xref rid="cam45552-bib-0022" ref-type="bibr"><sup>22</sup></xref> PACCT was a multi‐site, multi‐level study with two phases, each involving an independent communication intervention. The first phase, reported here, included a randomized clinical trial of a patient‐focused communication intervention. The second phase involved a physician‐focused communication training intervention that provided patient‐centered communication strategies and encouragement to discuss trials with all potentially eligible patients, regardless of race or other sociodemographic circumstances, using high‐quality, patient‐centered communication. Here we report on data from Phase 1, because, although the physician intervention was implemented and found to be acceptable and effective,<xref rid="cam45552-bib-0023" ref-type="bibr"><sup>23</sup></xref> data collection for Phase 2 was disrupted by the COVID pandemic and could not be completed.<xref rid="cam45552-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam45552-bib-0025" ref-type="bibr"><sup>25</sup></xref> This disruption also led to some adjustments in both outcome measures and analysis, described below.</p>
              </sec>
              <sec id="cam45552-sec-0008">
                <label>2.2</label>
                <title>Settings and participants</title>
                <p>PACCT was conducted at two National Cancer Institute‐designated comprehensive cancer centers: Wayne State University/Karmanos Cancer Institute (WSU/KCI) in Detroit, Michigan, and Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center (SKCCC) in Baltimore, Maryland. Physicians (medical oncologists, urologists, and radiation oncologists) were eligible to participate if they treated patients with prostate cancer and could recruit patients to available trials. Adult men were eligible if they had a confirmed diagnosis of prostate cancer (locally‐advanced to metastatic); self‐identified as Black, African American, or White and non‐Hispanic; had an ongoing but relatively brief (&lt;1 year) relationship with a participating physician and expected to see the physician at least once in the following year; could read and write English; and could potentially qualify for a therapeutic clinical trial within 2 years of consent (e.g., good performance status, no significant comorbidities). Although patients were technically eligible to participate if they had a confirmed diagnosis of prostate cancer, recruitment of patients with intermediate‐ to high‐risk prostate cancer was prioritized because they were more likely to become eligible for a therapeutic clinical trial than patients with early‐stage, low‐risk disease. Any open prostate cancer trial was appropriate, spanning from peri‐operative, radiation‐based, or drug therapy for recurrent or metastatic disease. The study was approved by the institutional review boards at each site and registered at <ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">Clinicaltrials.gov</ext-link> (identifier NCT02906241). All participants provided consent and received gift cards for participating.</p>
              </sec>
              <sec id="cam45552-sec-0009">
                <label>2.3</label>
                <title>Procedures</title>
                <p>Physicians were recruited at each site through information sessions and individual meetings to explain procedures and complete consent documents and baseline surveys. Patient recruitment procedures were designed to enroll similar patient numbers across physicians and across patient race (i.e., stratified by physician and race). Research staff identified eligible patients by examining upcoming appointments for participating physicians. Clinic staff informed eligible patients of the study and assessed interest. Research staff met with interested patients to explain the study, obtain consent, and administer baseline surveys. Then, research staff tracked participating patients for up to 2 years to identify those who had a scheduled appointment with a participating physician and were potentially eligible for an available therapeutic clinical trial, indicating there may be a trial discussion and invitation. These identified patients were asked to participate in the randomized controlled trial. This involved completing surveys before and after clinical interactions with a participating physician, being randomized to receive the communication intervention or usual care, and having their interaction with the physician video recorded. All surveys were completed using Qualtrics© survey software. Qualtrics randomly assigned patients to either the usual care or intervention group (1:1). Patients randomized to usual care participated in all study procedures, but did not receive the communication intervention. At the end of the two‐year period, research staff examined patient medical records to determine whether patients had received an invitation to participate in a therapeutic clinical trial.</p>
                <sec id="cam45552-sec-0010">
                  <label>2.3.1</label>
                  <title>Patient intervention</title>
                  <p>The intervention was a paper brochure with attitude and communication components. The brochure included text and graphics specifically designed to portray inclusion of Black men (e.g., two of three photos in the brochure were of Black men). The attitude component was based on the Common Ingroup Identity Model,<xref rid="cam45552-bib-0026" ref-type="bibr"><sup>26</sup></xref> which posits that a sense of common identity or purpose increases cooperation and trust among individuals from different social backgrounds. The brochure attempted to create this identity by explaining that patients and physicians have equally important roles and should work together as a team to provide the best care for the patient's cancer. The communication component was a Question Prompt List (QPL) which included a list of questions related to clinical trials. QPLs have been used in several settings to improve clinical communication by encouraging patients to participate actively during medical visits, for example, by asking questions and stating their concerns.<xref rid="cam45552-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cam45552-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="cam45552-bib-0029" ref-type="bibr"><sup>29</sup></xref> The QPL for PACCT was adapted from two existing QPLs with demonstrated effectiveness in similar populations and settings,<xref rid="cam45552-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="cam45552-bib-0031" ref-type="bibr"><sup>31</sup></xref> and pilot‐tested for acceptability with Black and White men. Research staff handed the brochure to patients in person and invited them to read through it, explaining briefly that patients might find it helpful during the clinic visit, especially if they discuss a clinical trial with their doctor. Research assistants were trained to encourage patients to ask questions during clinic visits, and to avoid answering questions or discussing trials.</p>
                </sec>
              </sec>
              <sec id="cam45552-sec-0011">
                <label>2.4</label>
                <title>Measures</title>
                <p>The primary outcome for the prospective observational study was potential <italic toggle="yes">eligibility</italic> for an available therapeutic clinical trial (yes/no). Research assistants determined potential eligibility by reviewing medical records of patients with an upcoming appointment to see a participating physician, and matching their recent clinical status to eligibility requirements for available prostate cancer therapeutic clinical trials.</p>
                <p>The outcomes for the prospective RCT were <italic toggle="yes">communication quality</italic> and <italic toggle="yes">invitation</italic> to participate in a specific therapeutic clinical trial. <italic toggle="yes">Communication quality</italic> during video‐recorded clinic visits was measured by patient self‐reports and observer ratings of patient active participation and physician patient‐centered communication (PCC). Patients and trained observers rated patient active participation using a measure assessing the extent to which patients engaged in each of seven behaviors, such as asking the doctor to explain treatments in greater detail.<xref rid="cam45552-bib-0031" ref-type="bibr"><sup>31</sup></xref> They rated physician PCC using a measure assessing the extent to which physicians engaged in each of the 12 behaviors. This measure has three subscales: informativeness (e.g., “doctor was very informative about patient's health”), supportiveness (e.g., “doctor made patient feel completely at ease”), and partnership‐building (e.g., “doctor asked for patient's thoughts about their health”).<xref rid="cam45552-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="cam45552-bib-0032" ref-type="bibr"><sup>32</sup></xref> Patients completed measures following their clinic visits. Observers were trained to observe the video‐recorded interactions and apply the measures. <italic toggle="yes">Invitation</italic> to a participate in a clinical trial was assessed by a single “yes/no” item determined by a review of patient medical records at the end of study enrollment.</p>
                <p>Patient baseline measures included self‐reported socio‐demographic characteristics (race, age, income, education, health literacy<xref rid="cam45552-bib-0033" ref-type="bibr"><sup>33</sup></xref>) and perceived health status.<xref rid="cam45552-bib-0034" ref-type="bibr"><sup>34</sup></xref>
</p>
              </sec>
              <sec id="cam45552-sec-0012">
                <label>2.5</label>
                <title>Sample size and statistical methods</title>
                <p>For the prospective observational study, univariable and multivariable logistic mixed‐effects models with institution as a random effect were used to explore factors associated with potential trial eligibility. These factors included sociodemographic characteristics (race, age, education, income, health literacy) and perceived health status.</p>
                <p>For the prospective intervention study, the planned study sample size was 16 patients per physician and 24 physicians (i.e., 384 patients) using the person‐level multi‐site/block trial design within Optimal Design,<xref rid="cam45552-bib-0035" ref-type="bibr"><sup>35</sup></xref> with the aim of achieving more than 95% power to detect a medium effect size of 0.5 at a 5% error. We further estimated that 169 eligible patients would have a video‐recorded trial discussion, producing at least 80% power to detect a medium effect size of 0.5 at a 5% error. However, the final sample for the prospective intervention study was small, and thus underpowered. Consequently, all statistical analyses were descriptive; no inferential analyses were conducted. Patient‐ and observer‐reported communication outcomes were summarized with means and standard deviations (SD) by study arm and race. Invitations to participate were summarized with counts and percentages by study arm and race.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cam45552-sec-0013">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="cam45552-sec-0014">
                <label>3.1</label>
                <title>Characteristics of study participants</title>
                <p>Figure <xref rid="cam45552-fig-0001" ref-type="fig">1</xref> shows patient participant flow and reasons for exclusions. During the study period (November 2016–January 2019), 476 patients of 18 physicians (10 at KCI, 8 at SKCCC) were screened. Of these, 156 (32.8%) patients were excluded because they were found to be ineligible (<italic toggle="yes">n</italic> = 79), their physician refused to refer them (<italic toggle="yes">n</italic> = 32), or they did not appear for their appointment (<italic toggle="yes">n</italic> = 45). Of the remaining 320 patients, 114 (35.6%) actively or passively declined, and 206 (64.4%) consented. Seven consented participants were excluded because they did not complete baseline surveys, were lost to follow‐up, or died. Table <xref rid="cam45552-tbl-0001" ref-type="table">1</xref> provides baseline characteristics of patients included in the observational study (<italic toggle="yes">n</italic> = 199). Of these, 44 (22.1%) were found to be eligible for an available trial and were randomly assigned to either intervention or usual care in the intervention study. Of the intent‐to‐treat (ITT) population, 21 (47.7%) were randomized to the intervention group; two did not receive the intervention because they did not have time to complete it prior to their physician visit and were switched to the usual care group. Thus, in the modified intent‐to‐treat (mITT) sample (<italic toggle="yes">n</italic> = 44), 19 patients were in the intervention group and 25 in the usual care group. These patients were seen by a total of nine physicians, with usual care patients seen by eight physicians and intervention patients seen by six physicians. Table <xref rid="cam45552-tbl-0001" ref-type="table">1</xref> provides baseline characteristics of these 44 participants by study arm. Of note, patient baseline characteristics were comparable between the two groups, although health literacy and income were higher in the usual care group.</p>
                <fig position="float" fig-type="FIGURE" id="cam45552-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>PACCT phase 1 participant CONSORT diagram.</p>
                  </caption>
                  <graphic xlink:href="CAM4-12-8604-g002" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="cam45552-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Patient baseline characteristics.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Prospective observational study</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Prospective intervention study</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 199)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 44)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Usual care (<italic toggle="yes">n</italic> = 25)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention (<italic toggle="yes">n</italic> = 19)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Race ‐ no. (%)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">91 (45.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20 (45.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (40.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (52.6)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">108 (54.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24 (54.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 (60.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9 (47.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age at consent ‐ mean (SD)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">65.61 (8.38)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">66.52 (8.50)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">66.80 (8.03)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">66.16 (9.30)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Education level‐ no. (%)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Less than HS/High School/GED</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">64 (32.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14 (31.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (32.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (31.6)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Some College/College Degree</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">80 (40.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19 (43.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (40.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9 (47.4)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Graduate/Professional Degree</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">55 (27.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11 (25.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (28.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (21.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Household income ‐ no. (%)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Less than $40,000</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">56 (29.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (19.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (16.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (23.5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">$40,000 ‐ $79,999</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">51 (27.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14 (34.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (29.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (41.2)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">$80,000 or more</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">82 (43.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19 (46.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13 (54.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (35.3)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Perceived health status‐ mean (SD)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.54 (0.53)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.61 (0.52)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.57 (0.48)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.67 (0.57)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Health literacy ‐ mean (SD)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.01 (1.01)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.89 (0.95)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.05 (0.89)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.67 (0.99)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Study Site ‐ no. (%)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Karmanos Cancer Institute</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">109 (54.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30 (68.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 (60)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 (78.9)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sidney Kimmel Comprehensive Cancer Center</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">90 (45.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14 (31.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (40)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (21.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam45552-ntgp-0001">
                    <fn id="cam45552-note-0001">
                      <p>Abbreviation: SD, standard deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cam45552-sec-0015">
                <label>3.2</label>
                <title>Observational study results</title>
                <p>Only 22.1% (<italic toggle="yes">n</italic> = 44) of study participants were potentially eligible for an available therapeutic trial during the study period. The only characteristic associated with eligibility was income in the multivariable analysis; patients with higher incomes were more often eligible than those with lower incomes (25.2% [=33/131] vs. 14.5% [=8/55]; Table <xref rid="cam45552-tbl-0002" ref-type="table">2</xref>). Compared to patients with incomes of &lt;$40,000, patients with incomes of $40,000–$79,999 were more often eligible for a clinical trial (28.0% vs. 14.5%; adjusted OR, 4.40 [SD, 1.81]), as were those with incomes of &gt;$80,000 (23.5% vs. 14.5%; adjusted OR, 6.06 [SD, 1.97]).</p>
                <table-wrap position="float" id="cam45552-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Univariable and multivariable logistic mixed‐effects regression analyses of factors associated with eligibility (eligible vs. ineligible, ineligible as reference).</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Univariable (<italic toggle="yes">n</italic> = 44)</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariable (<italic toggle="yes">n</italic> = 41)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Eligible patients/Total (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">OR (SE)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Eligible patients/Total (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">OR (SE)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Race</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20/91 (22.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">Ref.</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19/85 (22.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">Ref.</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24/108 (22.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.07 (1.42)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22/101 (21.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.65 (1.56)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age at consent</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">44/199 (22.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.02 (1.02)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">41/186 (22.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.03 (1.03)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Education level</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Less than HS/High School/GED</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14/64 (21.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">Ref.</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14/58 (24.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">Ref.</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Some College/College Degree</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19/80 (23.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.20 (1.51)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16/74 (21.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.64 (1.65)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Graduate/Professional Degree</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11/55 (20.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.99 (1.61)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11/54 (20.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.50 (1.84)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Household income</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Less than $40,000</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8/56 (14.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">Ref.</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8/55 (14.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">Ref.</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">$40,000–$79,000</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14/51 (27.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.75 (1.67)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14/50 (28.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.40 (1.81)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Over $80,000</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19/82 (23.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.36 (1.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19/81 (23.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6.06 (1.97)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Perceived health status</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">44/197 (22.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.35 (1.36)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">41/186 (22.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.82 (1.44)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Health literacy</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">44/198 (22.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.88 (1.18)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">41/186 (22.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.84 (1.24)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam45552-ntgp-0002">
                    <fn id="cam45552-note-0002">
                      <p><italic toggle="yes">Note</italic>: Eligible Patients/Total (%), numbers of events (eligible patients) and patients, and percentage of eligible patients; OR, odds ratio; SE, standard error.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cam45552-sec-0016">
                <label>3.3</label>
                <title>Intervention study results</title>
                <p>Mean levels of patient active participation and physician patient‐centered communication were similar in the intervention and usual care groups (Table <xref rid="cam45552-tbl-0003" ref-type="table">3</xref>), and most were also similar across racial groups. However, Black intervention patients reported somewhat higher active participation than those in the usual care group (Intervention vs. Usual care; mean [SD], 4.14 [1.03] vs. 3.74 [0.99]), whereas White intervention patients reported somewhat lower active participation than those in the usual care group (4.11 [0.40] vs. 4.43 [0.62]). However, wide variation around these means preclude conclusions about reliable differences across these groups.</p>
                <table-wrap position="float" id="cam45552-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Patient‐ and observer‐reported communication outcomes by study arm.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/>
                        <th align="left" colspan="6" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Communication outcomes—mean (SD)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Patient‐reported</th>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Observer‐reported</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 44)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Usual care (<italic toggle="yes">n</italic> = 25)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention (<italic toggle="yes">n</italic> = 19)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 44)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Usual care (<italic toggle="yes">n</italic> = 25)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention (<italic toggle="yes">n</italic> = 19)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Pat active participation</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.14 (0.60)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.14 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.13 (0.56)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.79 (1.03)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.89 (0.88)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.66 (1.19)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.94 (1.04)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.74 (0.99)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.14 (1.03)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.56 (1.50)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.70 (1.59)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.43 (1.46)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.30 (0.59)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.43 (0.62)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.11 (0.40)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.99 (1.37)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.01 (1.05)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.95 (1.98)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Physician PCC: Information‐giving</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.50 (0.54)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.57 (0.50)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.41 (0.54)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.16 (0.54)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.21 (0.50)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.11 (0.58)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.47 (0.85)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.45 (0.82)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.50 (0.87)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.21 (0.91)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.39 (0.61)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.05 (1.02)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.52 (0.67)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.66 (0.62)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.31 (0.62)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.12 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.09 (0.69)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.19 (0.43)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Physician PCC: Supportiveness</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.43 (0.43)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.48 (0.45)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.37 (0.42)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.08 (0.59)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.17 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.96 (0.53)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.44 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.38 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.50 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.93 (1.00)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.03 (1.32)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.85 (0.74)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.42 (0.60)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.55 (0.61)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.22 (0.47)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.20 (0.67)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.27 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.09 (0.75)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Physician PCC: Partnership‐building</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.22 (0.59)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.23 (0.70)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.20 (0.47)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.84 (0.49)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.90 (0.46)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.76 (0.53)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.12 (0.95)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.08 (1.26)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.17 (0.66)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.76 (1.00)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.89 (1.17)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.65 (0.87)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.29 (0.75)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.34 (0.79)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.22 (0.71)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.91 (0.34)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.91 (0.27)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.91 (0.49)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Physician PCC: Total</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.38 (0.47)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.43 (0.51)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.32 (0.43)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.03 (0.42)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.09 (0.38)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.94 (0.47)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.35 (0.74)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.30 (0.85)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.39 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.97 (0.82)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.10 (0.81)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3.85 (0.78)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.41 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.52 (0.64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.25 (0.58)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.08 (0.38)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.09 (0.39)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.06 (0.37)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam45552-ntgp-0003">
                    <fn id="cam45552-note-0003">
                      <p>Abbreviations: PCC, patient‐centered communication; SD, standard deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Regarding rates of invitation to participate in clinical trials, 73.7% of intervention participants compared to 60.0% of usual care participants received an invitation (Table <xref rid="cam45552-tbl-0004" ref-type="table">4</xref>). This difference in invitation rates by study arm was larger among Black men (Intervention vs. Usual care, 80.0% [=8/10] vs. 30.0% [=3/10]) than among White men (66.7% [=6/9] vs. 80.0% [=12/15]).</p>
                <table-wrap position="float" id="cam45552-tbl-0004" content-type="TABLE">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Clinical trial invitation by study arm and patient race.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Number of trial invitations/total patients (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Usual care</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Clinical trial invitation</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15/25 (60.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14/19 (73.7)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3/10 (30.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8/10 (80.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12/15 (80.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6/9 (66.7)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam45552-ntgp-0004">
                    <fn id="cam45552-note-0004">
                      <p><italic toggle="yes">Note</italic>: Number of trial invitations/total patients (%), numbers of events (invitations) and patients, and percentage of invited patients.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cam45552-sec-0017">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>Participation in cancer clinical trials is consistently and persistently low, reflecting inequitable access to high‐quality care. This study is among the first to examine multilevel enrollment barriers and to examine an intervention to increase enrollment among Black and White patients who are potentially eligible for an available therapeutic trial.</p>
              <p>The first barrier we examined was eligibility, a system‐level barrier. Findings showed that less than a quarter of participants qualified for an available trial over the two‐year period they were enrolled in the study. This small proportion was surprising, given that the study participants were receiving care at major academic institutions and had a disease associated with many therapeutic trials. Also, despite research suggesting that trial participation is associated with age, race, and other sociodemographic characteristics,<xref rid="cam45552-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam45552-bib-0020" ref-type="bibr"><sup>20</sup></xref> the only characteristic associated with eligibility was income. Prior studies have found that higher socioeconomic status (SES) is associated with higher prostate cancer incidence, lower likelihood of presenting with metastatic disease at the time of diagnosis, and lower mortality rates of prostate cancer.<xref rid="cam45552-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="cam45552-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="cam45552-bib-0037" ref-type="bibr"><sup>37</sup></xref> These associations are presumably due to greater access to healthcare among those with higher SES. However, this is one of the very few studies to specifically examine the association between SES and clinical trial participation.<xref rid="cam45552-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="cam45552-bib-0038" ref-type="bibr"><sup>38</sup></xref> Future studies are needed to not only further document the extent to which SES affects clinical trial enrollment, but also test interventions to mitigate these effects. Interventions may include, for example, offering patients the ability to participate in some aspects of a trial in their local clinics (e.g., blood draws, scans); providing transportation to clinical trial research sites; and compensating patients for trial‐related time and expenses.</p>
              <p>Together, these findings provide further evidence that the greatest barrier to enrollment may be restrictive eligibility criteria—most patients do not qualify.<xref rid="cam45552-bib-0039" ref-type="bibr"><sup>39</sup></xref> Thus, interventions targeting patients' attitudes and perception of trials may be misguided, and in fact, may cause backlash in the form of greater mistrust when patients learn the value of participation, only to discover they do not qualify. Several professional organizations have published recommendations for addressing inequitable enrollment.<xref rid="cam45552-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="cam45552-bib-0040" ref-type="bibr"><sup>40</sup></xref> Recommendations include, for example, designing and implementing trials with a specific focus on reducing barriers and enhancing equity, diversity, and inclusion (EDI); requiring training and a commitment to achieving EDI for investigators, sponsors, and policymakers, and shifting to a paradigm that prioritizes the interests and voices of the community. PACCT's protocol, for example, required recruiting an equal number of Black and White patients per physician, which required recruiters to make extra efforts to achieve equitable enrollment.<xref rid="cam45552-bib-0022" ref-type="bibr"><sup>22</sup></xref> Such strategies could improve inclusiveness, access and enrollment, thereby improving the generalizability of results and accelerating the pace of scientific progress.<xref rid="cam45552-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="cam45552-bib-0041" ref-type="bibr"><sup>41</sup></xref> Additionally, findings suggest that published enrollment rates should consider not only all patients, but also all <italic toggle="yes">eligible</italic> patients as a meaningful denominator, thus providing more accurate data on the sources of low enrollment and potential intervention targets.<xref rid="cam45552-bib-0042" ref-type="bibr"><sup>42</sup></xref>
</p>
              <p>The second enrollment barrier we addressed was interpersonal: patient–physician communication quality in interactions with potentially eligible patients. This low‐cost, patient‐focused communication intervention was based on the assumption that, while patient–physician clinical communication is the most central and proximal influence on invitations to participate and actual trial participation, communication about trials may be infrequent or of low‐quality, especially for Black patients.<xref rid="cam45552-bib-0043" ref-type="bibr"><sup>43</sup></xref> The intervention was designed to encourage patients to participate actively in clinical interactions to improve communication quality and prompt invitations to participate. Although the study sample was very small and results must be interpreted with caution, the intervention showed improved outcomes, especially among Black participants, as we expected. Compared to usual care patients, Black intervention patients reported participating more actively in clinical interactions, such as by asking questions and stating concerns. While this finding is promising, questions remain about why White intervention patients reported <italic toggle="yes">less</italic> active participation. Perhaps of greater importance, both Black and White intervention patients received more trial invitations than usual care patients, and Black intervention patients received more invitations than White intervention patients.</p>
              <p>This study should be interpreted within its limitations. The sample size was small due to the COVID‐19 pandemic disruptions,<xref rid="cam45552-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam45552-bib-0025" ref-type="bibr"><sup>25</sup></xref> which occurred at the beginning of Phase 2 of the study. Most clinical trials were paused and hospitals prohibited research staff from entering the clinics. Thus, this study includes only data from Phase 1, limiting originally‐planned analyses and suggesting caution in interpreting findings. We could not examine some planned outcomes, including patient decisions to participate and actual enrollment rates. We also could not test the effects of the physician‐focused communication intervention on outcomes. Thus, future research is needed in a larger sample to complete these analyses.</p>
              <p>Additionally, the study included only Black and White men with one type of cancer, and was conducted at major academic centers, limiting the generalizability of the study. Future studies should include a broader population, such as patients receiving care at community cancer centers,<xref rid="cam45552-bib-0044" ref-type="bibr"><sup>44</sup></xref> where the two barriers addressed here may be more pronounced.</p>
              <p>Despite these limitations, this study suggests ways to improve equitable clinical trial enrollment. Suggested strategies include broadening trial eligibility criteria to better reflect and include diverse patient populations; reporting trial enrollment rates not just among all people with cancer, but also among those potentially eligible for an available trial as a way to identify potential intervention targets; and implementing low‐cost communication interventions, such as the one described here—a low‐cost, highly scalable intervention that may improve patient‐provider communication and invitations to participate in clinical trials, and shows specific benefit for Black patients, who have been historically excluded from or mistreated in clinical trials.</p>
            </sec>
            <sec id="cam45552-sec-0020">
              <title>PRECIS</title>
              <p>This multisite study addressed two barriers to enrollment of Black and White men in prostate cancer clinical trials. Findings showed that eligibility, a systemic barrier, is the biggest barrier, but that a communication intervention can improve interpersonal barriers including communication quality and trial invitation rates, especially for Black patients.</p>
            </sec>
            <sec id="cam45552-sec-0023">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Susan Eggly:</bold> Conceptualization (equal); data curation (equal); formal analysis (equal); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); supervision (equal); writing – original draft (equal); writing – review and editing (equal). <bold>Nicole Senft:</bold> Conceptualization (equal); formal analysis (equal); methodology (equal); writing – review and editing (equal). <bold>Seongho Kim:</bold> Formal analysis (equal); methodology (equal); writing – review and editing (equal). <bold>Elisabeth I Heath:</bold> Conceptualization (equal); methodology (equal); writing – review and editing (equal). <bold>Hyejeong Jang:</bold> Formal analysis (equal); writing – review and editing (equal). <bold>Tanina Foster:</bold> Formal analysis (equal); project administration (equal); writing – review and editing (equal). <bold>Fatmeh Baidoun:</bold> Project administration (equal); writing – review and editing (equal). <bold>Mark Manning:</bold> Conceptualization (equal); formal analysis (equal); methodology (equal); writing – review and editing (equal). <bold>Louis A. Penner:</bold> Conceptualization (equal); formal analysis (equal); methodology (equal); writing – review and editing (equal). <bold>Terrance Albrecht:</bold> Conceptualization (equal); methodology (equal); writing – review and editing (equal). <bold>Michael A Carducci:</bold> Conceptualization (equal); project administration (equal); supervision (equal); writing – review and editing (equal). <bold>Dina Lansey:</bold> Conceptualization (equal); project administration (equal); writing – review and editing (equal). <bold>Lauren Hamel:</bold> Conceptualization (equal); formal analysis (equal); methodology (equal); writing – review and editing (equal).</p>
            </sec>
            <sec id="cam45552-sec-0018">
              <title>FUNDING INFORMATION</title>
              <p>This research was supported by the National Institutes of Health/National Cancer Institute Grant No. R01CA200718 (S.E)</p>
            </sec>
            <sec sec-type="COI-statement" id="cam45552-sec-0019">
              <title>CONFLICT OF INTEREST</title>
              <p>The following authors report no conflict of interest: Susan Eggly, Nicole Senft, Seongho Kim, Tanina Foster Moore, Fatmeh Baidoun, Mark Manning, Louis Penner, Terrance Albrecht, Michael Carducci, Dina Lansey, and Lauren Hamel. Elisabeth Heath reports serving as consultant for Astellas Pharma and on the Ad Board and/or Speakers' Bureau for Astra Zeneca, Sanofi, and Bayer.</p>
            </sec>
          </body>
          <back>
            <sec sec-type="data-availability" id="cam45552-sec-0022">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available on request from the corresponding author.</p>
            </sec>
            <ref-list content-type="cited-references" id="cam45552-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cam45552-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0001"><string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Cook</surname><given-names>E</given-names></string-name>, <string-name><surname>Tai</surname><given-names>E</given-names></string-name>, <string-name><surname>Bleyer</surname><given-names>A</given-names></string-name>. <article-title>The role of clinical trial participation in cancer research: barriers, evidence, and strategies</article-title>. <source>Am Soc Clin Oncol Educ Book</source>. <year>2016</year>;<volume>35</volume>:<fpage>185</fpage>‐<lpage>198</lpage>.<pub-id pub-id-type="pmid">27249699</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0002"><string-name><surname>Freedman</surname><given-names>LS</given-names></string-name>, <string-name><surname>Simon</surname><given-names>R</given-names></string-name>, <string-name><surname>Foulkes</surname><given-names>MA</given-names></string-name>, et al. <article-title>Inclusion of women and minorities in clinical trials and the NIH revitalization act of 1993‐‐the perspective of NIH clinical trialists</article-title>. <source>Control Clin Trials</source>. <year>1995</year>;<volume>16</volume>(<issue>5</issue>):<fpage>277</fpage>‐<lpage>285</lpage>. discussion 286–279, 293–309.<pub-id pub-id-type="pmid">8582146</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0003"><string-name><surname>Oyer</surname><given-names>RA</given-names></string-name>, <string-name><surname>Hurley</surname><given-names>P</given-names></string-name>, <string-name><surname>Boehmer</surname><given-names>L</given-names></string-name>, et al. <article-title>Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>19</issue>):<fpage>2163</fpage>‐<lpage>2171</lpage>.<pub-id pub-id-type="pmid">35588469</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0004"><string-name><surname>Duma</surname><given-names>N</given-names></string-name>, <string-name><surname>Vera Aguilera</surname><given-names>J</given-names></string-name>, <string-name><surname>Paludo</surname><given-names>J</given-names></string-name>, et al. <article-title>Representation of minorities and women in oncology clinical trials: review of the past 14 years</article-title>. <source>J Oncol Pract</source>. <year>2018</year>;<volume>14</volume>(<issue>1</issue>):<fpage>e1</fpage>‐<lpage>e10</lpage>.<pub-id pub-id-type="pmid">29099678</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0005"><string-name><surname>Loree</surname><given-names>JM</given-names></string-name>, <string-name><surname>Anand</surname><given-names>S</given-names></string-name>, <string-name><surname>Dasari</surname><given-names>A</given-names></string-name>, et al. <article-title>Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018</article-title>. <source>JAMA Oncol</source>. <year>2019</year>;<volume>5</volume>:<elocation-id>e191870</elocation-id>.<pub-id pub-id-type="pmid">31415071</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0006"><string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hershman</surname><given-names>DL</given-names></string-name>, <string-name><surname>Osarogiagbon</surname><given-names>RU</given-names></string-name>, et al. <article-title>Representativeness of black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies</article-title>. <source>JNCI Cancer Spectr</source>. <year>2020</year>;<volume>4</volume>(<issue>4</issue>):<fpage>pkaa034</fpage>.<pub-id pub-id-type="pmid">32704619</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0007"><string-name><surname>Wissing</surname><given-names>MD</given-names></string-name>, <string-name><surname>Kluetz</surname><given-names>PG</given-names></string-name>, <string-name><surname>Ning</surname><given-names>YM</given-names></string-name>, et al. <article-title>Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013</article-title>. <source>Cancer</source>. <year>2014</year>;<volume>120</volume>(<issue>19</issue>):<fpage>3025</fpage>‐<lpage>3032</lpage>.<pub-id pub-id-type="pmid">24965506</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="book" id="cam45552-cit-0008"><collab collab-type="authors">National Academies of Sciences, Engineering, and Medicine</collab>
. <source>Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups</source>. <publisher-name>The National Academies Press</publisher-name>; <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0009"><string-name><surname>Banda</surname><given-names>DR</given-names></string-name>, <string-name><surname>Germain</surname><given-names>DS</given-names></string-name>, <string-name><surname>McCaskill‐Stevens</surname><given-names>W</given-names></string-name>, <string-name><surname>Ford</surname><given-names>JG</given-names></string-name>, <string-name><surname>Swain</surname><given-names>SM</given-names></string-name>. <article-title>A critical review of the enrollment of black patients in cancer clinical trials</article-title>. <source>Am Soc Clin Oncol Educ Book</source>. <year>2012</year>;<volume>32</volume>(<issue>1</issue>):<fpage>153</fpage>‐<lpage>157</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="book" id="cam45552-cit-0010"><string-name><surname>Nass</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Moses</surname><given-names>HL</given-names></string-name>, <string-name><surname>Mendelsohn</surname><given-names>J</given-names></string-name>. <source>A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program</source>. <publisher-name>Institute of Medicine, Committee on Cancer Clinical Trials and the NCI Cooperative Group Program</publisher-name>; <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0011"><string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>HE</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name>. <article-title>Cancer statistics, 2022</article-title>. <source>CA Cancer J Clin</source>. <year>2022</year>;<volume>72</volume>(<issue>1</issue>):<fpage>7</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">35020204</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0012"><string-name><surname>Giaquinto</surname><given-names>AN</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Tossas</surname><given-names>KY</given-names></string-name>, <string-name><surname>Winn</surname><given-names>RA</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>. <article-title>Cancer statistics for African American/black people 2022</article-title>. <source>CA Cancer J Clin</source>. <year>2022</year>;<volume>72</volume>(<issue>3</issue>):<fpage>202</fpage>‐<lpage>229</lpage>.<pub-id pub-id-type="pmid">35143040</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0013"><string-name><surname>Rencsok</surname><given-names>EM</given-names></string-name>, <string-name><surname>Bazzi</surname><given-names>LA</given-names></string-name>, <string-name><surname>McKay</surname><given-names>RR</given-names></string-name>, et al. <article-title>Diversity of enrollment in prostate cancer clinical trials: current status and future directions</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2020</year>;<volume>29</volume>(<issue>7</issue>):<fpage>1374</fpage>‐<lpage>1380</lpage>.<pub-id pub-id-type="pmid">32503813</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0014"><string-name><surname>Owens‐Walton</surname><given-names>J</given-names></string-name>, <string-name><surname>Williams</surname><given-names>C</given-names></string-name>, <string-name><surname>Rompre‐Brodeur</surname><given-names>A</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>PA</given-names></string-name>, <string-name><surname>Ball</surname><given-names>MW</given-names></string-name>. <article-title>Minority enrollment in phase II and III clinical trials in urologic oncology</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>:<fpage>JCO2101885</fpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0015"><string-name><surname>Balakrishnan</surname><given-names>AS</given-names></string-name>, <string-name><surname>Palmer</surname><given-names>NR</given-names></string-name>, <string-name><surname>Fergus</surname><given-names>KB</given-names></string-name>, et al. <article-title>Minority recruitment trends in phase III prostate cancer clinical trials (2003 to 2014): progress and critical areas for improvement</article-title>. <source>J Urol</source>. <year>2019</year>;<volume>201</volume>(<issue>2</issue>):<fpage>259</fpage>‐<lpage>267</lpage>.<pub-id pub-id-type="pmid">30218761</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0016"><string-name><surname>Hamel</surname><given-names>LM</given-names></string-name>, <string-name><surname>Penner</surname><given-names>LA</given-names></string-name>, <string-name><surname>Albrecht</surname><given-names>TL</given-names></string-name>, <string-name><surname>Heath</surname><given-names>E</given-names></string-name>, <string-name><surname>Gwede</surname><given-names>CK</given-names></string-name>, <string-name><surname>Eggly</surname><given-names>S</given-names></string-name>. <article-title>Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer</article-title>. <source>Cancer Control</source>. <year>2016</year>;<volume>23</volume>(<issue>4</issue>):<fpage>327</fpage>‐<lpage>337</lpage>.<pub-id pub-id-type="pmid">27842322</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0017"><string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hershman</surname><given-names>DL</given-names></string-name>, <string-name><surname>Till</surname><given-names>C</given-names></string-name>, et al. <article-title>"when offered to participate": a systematic review and meta‐analysis of patient agreement to participate in cancer clinical trials</article-title>. <source>J Natl Cancer Inst</source>. <year>2021</year>;<volume>113</volume>(<issue>3</issue>):<fpage>244</fpage>‐<lpage>257</lpage>.<pub-id pub-id-type="pmid">33022716</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0018"><string-name><surname>Senft</surname><given-names>N</given-names></string-name>, <string-name><surname>Hamel</surname><given-names>LM</given-names></string-name>, <string-name><surname>Manning</surname><given-names>MA</given-names></string-name>, et al. <article-title>Willingness to discuss clinical trials among black vs white men with prostate cancer</article-title>. <source>JAMA Oncologia</source>. <year>2020</year>;<volume>6</volume>(<issue>11</issue>):<fpage>1</fpage>‐<lpage>5</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0019"><string-name><surname>Langford</surname><given-names>AT</given-names></string-name>, <string-name><surname>Resnicow</surname><given-names>K</given-names></string-name>, <string-name><surname>Dimond</surname><given-names>EP</given-names></string-name>, et al. <article-title>Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's community cancer centers program</article-title>. <source>Cancer</source>. <year>2014</year>;<volume>120</volume>(<issue>6</issue>):<fpage>877</fpage>‐<lpage>884</lpage>.<pub-id pub-id-type="pmid">24327389</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0020"><string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Gralow</surname><given-names>JR</given-names></string-name>, <string-name><surname>Albain</surname><given-names>KS</given-names></string-name>, <string-name><surname>Ramsey</surname><given-names>SD</given-names></string-name>, <string-name><surname>Hershman</surname><given-names>DL</given-names></string-name>. <article-title>Patient income level and cancer clinical trial participation: a prospective survey study</article-title>. <source>JAMA Oncol</source>. <year>2016</year>;<volume>2</volume>(<issue>1</issue>):<fpage>137</fpage>‐<lpage>139</lpage>.<pub-id pub-id-type="pmid">26468994</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0021"><string-name><surname>Shen</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>EB</given-names></string-name>, <string-name><surname>Costas‐Muniz</surname><given-names>R</given-names></string-name>, et al. <article-title>The effects of race and racial concordance on patient‐physician communication: a systematic review of the literature</article-title>. <source>J Racial Ethn Health Disparities</source>. <year>2018</year>;<volume>5</volume>(<issue>1</issue>):<fpage>117</fpage>‐<lpage>140</lpage>.<pub-id pub-id-type="pmid">28275996</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0022"><string-name><surname>Eggly</surname><given-names>S</given-names></string-name>, <string-name><surname>Hamel</surname><given-names>LM</given-names></string-name>, <string-name><surname>Heath</surname><given-names>E</given-names></string-name>, et al. <article-title>Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials</article-title>. <source>BMC Cancer</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>807</fpage>.<pub-id pub-id-type="pmid">29197371</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0023"><string-name><surname>Eggly</surname><given-names>S</given-names></string-name>, <string-name><surname>Manning</surname><given-names>MA</given-names></string-name>, <string-name><surname>Senft</surname><given-names>N</given-names></string-name>, et al. <article-title>Development and pilot test of a physician‐focused cancer clinical trials communication training module</article-title>. <source>PEC Innovation</source>. <year>2022</year>;<volume>1</volume>:<elocation-id>100012</elocation-id>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0024"><string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>H</given-names></string-name>, <string-name><surname>LeBlanc</surname><given-names>M</given-names></string-name>, <string-name><surname>Hershman</surname><given-names>DL</given-names></string-name>, <string-name><surname>Blanke</surname><given-names>CD</given-names></string-name>. <article-title>Cancer clinical trial participation at the 1‐year anniversary of the outbreak of the COVID‐19 pandemic</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>7</issue>):<elocation-id>e2118433</elocation-id>.<pub-id pub-id-type="pmid">34323986</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0025"><string-name><surname>Lamont</surname><given-names>EB</given-names></string-name>, <string-name><surname>Diamond</surname><given-names>SS</given-names></string-name>, <string-name><surname>Katriel</surname><given-names>RG</given-names></string-name>, et al. <article-title>Trends in oncology clinical trials launched before and during the COVID‐19 pandemic</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>1</issue>):<elocation-id>e2036353</elocation-id>.<pub-id pub-id-type="pmid">33502481</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="book" id="cam45552-cit-0026"><string-name><surname>Gaertner</surname><given-names>S</given-names></string-name>, <string-name><surname>Dovidio</surname><given-names>JF</given-names></string-name>. <part-title>A common ingroup identity: a categorization‐based approach for reducing intergroup bias</part-title>. In: <person-group person-group-type="editor"><string-name><surname>Nelson</surname><given-names>T</given-names></string-name></person-group>, ed. <source>Handbook of Prejudice</source>. <publisher-name>Sage</publisher-name>; <year>2009</year>:<fpage>489</fpage>‐<lpage>505</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0027"><string-name><surname>Brandes</surname><given-names>K</given-names></string-name>, <string-name><surname>Linn</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Butow</surname><given-names>PN</given-names></string-name>, <string-name><surname>van Weert</surname><given-names>JC</given-names></string-name>. <article-title>The characteristics and effectiveness of question prompt list interventions in oncology: a systematic review of the literature</article-title>. <source>Psychooncology</source>. <year>2015</year>;<volume>24</volume>(<issue>3</issue>):<fpage>245</fpage>‐<lpage>252</lpage>.<pub-id pub-id-type="pmid">25082386</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0028"><string-name><surname>Henselmans</surname><given-names>I</given-names></string-name>, <string-name><surname>de Haes</surname><given-names>HC</given-names></string-name>, <string-name><surname>Smets</surname><given-names>EM</given-names></string-name>. <article-title>Enhancing patient participation in oncology consultations: a best evidence synthesis of patient‐targeted interventions</article-title>. <source>Psychooncology</source>. <year>2013</year>;<volume>22</volume>(<issue>5</issue>):<fpage>961</fpage>‐<lpage>977</lpage>.<pub-id pub-id-type="pmid">22585543</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0029"><string-name><surname>Sansoni</surname><given-names>JE</given-names></string-name>, <string-name><surname>Grootemaat</surname><given-names>P</given-names></string-name>, <string-name><surname>Duncan</surname><given-names>C</given-names></string-name>. <article-title>Question prompt lists in health consultations: a review</article-title>. <source>Patient Educ Couns</source>. <year>2015</year>;<volume>98</volume>:<fpage>1454</fpage>‐<lpage>1464</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0030"><string-name><surname>Brown</surname><given-names>RF</given-names></string-name>, <string-name><surname>Bylund</surname><given-names>CL</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Edgerson</surname><given-names>S</given-names></string-name>, <string-name><surname>Butow</surname><given-names>P</given-names></string-name>. <article-title>Testing the utility of a cancer clinical trial specific question prompt list (QPL‐CT) during oncology consultations</article-title>. <source>Patient Educ Couns</source>. <year>2012</year>;<volume>88</volume>(<issue>2</issue>):<fpage>311</fpage>‐<lpage>317</lpage>.<pub-id pub-id-type="pmid">22390854</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0031"><string-name><surname>Eggly</surname><given-names>S</given-names></string-name>, <string-name><surname>Hamel</surname><given-names>LM</given-names></string-name>, <string-name><surname>Foster</surname><given-names>TS</given-names></string-name>, et al. <article-title>Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists</article-title>. <source>Patient Educ Couns</source>. <year>2017</year>;<volume>100</volume>(<issue>5</issue>):<fpage>818</fpage>‐<lpage>826</lpage>.<pub-id pub-id-type="pmid">28073615</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0032"><string-name><surname>Street</surname><given-names>RL</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Gordon</surname><given-names>H</given-names></string-name>, <string-name><surname>Haidet</surname><given-names>P</given-names></string-name>. <article-title>Physicians' communication and perceptions of patients: is it how they look, how they talk, or is it just the doctor?</article-title><source>Soc Sci Med</source>. <year>2007</year>;<volume>65</volume>(<issue>3</issue>):<fpage>586</fpage>‐<lpage>598</lpage>.<pub-id pub-id-type="pmid">17462801</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0033"><string-name><surname>Schwartz</surname><given-names>KL</given-names></string-name>, <string-name><surname>Bartoces</surname><given-names>M</given-names></string-name>, <string-name><surname>Campbell‐Voytal</surname><given-names>K</given-names></string-name>, et al. <article-title>Estimating health literacy in family medicine clinics in metropolitan Detroit: a MetroNet study</article-title>. <source>J Am Board Fam Med</source>. <year>2013</year>;<volume>26</volume>(<issue>5</issue>):<fpage>566</fpage>‐<lpage>570</lpage>.<pub-id pub-id-type="pmid">24004708</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0034"><string-name><surname>Benson</surname><given-names>T</given-names></string-name>, <string-name><surname>Sizmur</surname><given-names>S</given-names></string-name>, <string-name><surname>Whatling</surname><given-names>J</given-names></string-name>, <string-name><surname>Arikan</surname><given-names>S</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>D</given-names></string-name>, <string-name><surname>Ingram</surname><given-names>D</given-names></string-name>. <article-title>Evaluation of a new short generic measure of health status: howRu</article-title>. <source>Inform Prim Care</source>. <year>2010</year>;<volume>18</volume>(<issue>2</issue>):<fpage>89</fpage>‐<lpage>101</lpage>.<pub-id pub-id-type="pmid">21078231</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="miscellaneous" id="cam45552-cit-0035"><article-title><italic toggle="yes">Optimal Design Plus Empirical (Version 3.01): HLM Software</italic> [computer program]</article-title>. <year>2011</year>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0036"><string-name><surname>Cheng</surname><given-names>I</given-names></string-name>, <string-name><surname>Witte</surname><given-names>JS</given-names></string-name>, <string-name><surname>McClure</surname><given-names>LA</given-names></string-name>, et al. <article-title>Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California</article-title>. <source>Cancer Causes Control</source>. <year>2009</year>;<volume>20</volume>(<issue>8</issue>):<fpage>1431</fpage>‐<lpage>1440</lpage>.<pub-id pub-id-type="pmid">19526319</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0037"><string-name><surname>Weiner</surname><given-names>AB</given-names></string-name>, <string-name><surname>Matulewicz</surname><given-names>RS</given-names></string-name>, <string-name><surname>Tosoian</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Feinglass</surname><given-names>JM</given-names></string-name>, <string-name><surname>Schaeffer</surname><given-names>EM</given-names></string-name>. <article-title>The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004‐2013)</article-title>. <source>Urol Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>3</issue>):<fpage>91.e91</fpage>‐<lpage>91.e96</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0038"><string-name><surname>Williams</surname><given-names>CP</given-names></string-name>, <string-name><surname>Senft Everson</surname><given-names>N</given-names></string-name>, <string-name><surname>Shelburne</surname><given-names>N</given-names></string-name>, <string-name><surname>Norton</surname><given-names>WE</given-names></string-name>. <article-title>Demographic and health behavior factors associated with clinical trial invitation and participation in the United States</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>9</issue>):<elocation-id>e2127792</elocation-id>.<pub-id pub-id-type="pmid">34586365</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0039"><string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hershman</surname><given-names>DL</given-names></string-name>, <string-name><surname>Fleury</surname><given-names>ME</given-names></string-name>, <string-name><surname>Vaidya</surname><given-names>R</given-names></string-name>. <article-title>Association of patient comorbid conditions with cancer clinical trial participation</article-title>. <source>JAMA Oncologia</source>. <year>2019</year>;<volume>5</volume>(<issue>3</issue>):<fpage>326</fpage>‐<lpage>333</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45552-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0040"><string-name><surname>Boyer‐Chammard</surname><given-names>A</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>TH</given-names></string-name>, <string-name><surname>Anton‐Culver</surname><given-names>H</given-names></string-name>. <article-title>Survival differences in breast cancer among racial/ethnic groups: a population‐based study</article-title>. <source>Cancer Detect Prev</source>. <year>1999</year>;<volume>23</volume>(<issue>6</issue>):<fpage>463</fpage>‐<lpage>473</lpage>.<pub-id pub-id-type="pmid">10571656</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0041"><string-name><surname>Kim</surname><given-names>ES</given-names></string-name>, <string-name><surname>Bruinooge</surname><given-names>SS</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>S</given-names></string-name>, et al. <article-title>Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of cancer research joint research statement</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>33</issue>):<fpage>3737</fpage>‐<lpage>3744</lpage>.<pub-id pub-id-type="pmid">28968170</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0042"><string-name><surname>Hamel</surname><given-names>LM</given-names></string-name>, <string-name><surname>Dougherty</surname><given-names>DW</given-names></string-name>, <string-name><surname>Albrecht</surname><given-names>TL</given-names></string-name>, et al. <article-title>Unpacking trial offers and low accrual rates: a qualitative analysis of clinic visits with physicians and patients potentially eligible for a prostate cancer clinical trial</article-title>. <source>JCO Oncol Pract</source>. <year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>e124</fpage>‐<lpage>e131</lpage>.<pub-id pub-id-type="pmid">31790330</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0043"><string-name><surname>Eggly</surname><given-names>S</given-names></string-name>, <string-name><surname>Barton</surname><given-names>E</given-names></string-name>, <string-name><surname>Winckles</surname><given-names>A</given-names></string-name>, <string-name><surname>Penner</surname><given-names>LA</given-names></string-name>, <string-name><surname>Albrecht</surname><given-names>TL</given-names></string-name>. <article-title>A disparity of words: racial differences in oncologist‐patient communication about clinical trials</article-title>. <source>Health Expect</source>. <year>2015</year>;<volume>18</volume>(<issue>5</issue>):<fpage>1316</fpage>‐<lpage>1326</lpage>.<pub-id pub-id-type="pmid">23910630</pub-id></mixed-citation>
              </ref>
              <ref id="cam45552-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="cam45552-cit-0044"><string-name><surname>Ramirez</surname><given-names>AG</given-names></string-name>, <string-name><surname>Chalela</surname><given-names>P</given-names></string-name>. <article-title>Equitable representation of Latinos in clinical research is needed to achieve health equity in cancer care</article-title>. <source>JCO Oncol Pract</source>. <year>2022</year>;<volume>18</volume>(<issue>5</issue>):<fpage>e797</fpage>‐<lpage>e804</lpage>.<pub-id pub-id-type="pmid">35544655</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
